Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…Abstract Number: 624 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention
Background/Purpose: Salivary dysfunction in Sjögren’s (SS) can lead to serious and costly oral complications including accelerated caries and, in some cases, loss of dentition. Clinical…Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS). Clinical practice guidelines were developed for…Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…Abstract Number: 627 • 2015 ACR/ARHP Annual Meeting
Clinical Subsets and Presenting Features in Primary Sjögren’s Syndrome: Results from a Single Center Inception Cohort Study
Background/Purpose: Aim of the study was to characterize the spectrum of presenting clinical features in a single-centre inception cohort of patients with primary Sjögren’s syndrome…Abstract Number: 628 • 2015 ACR/ARHP Annual Meeting
Poor Prognosis of Patients with Primary Sjögren Syndrome Who Fulfilled at Diagnosis the Classification Criteria for Concomitant Cryoglobulinemic Vasculitis
Background/Purpose: To evaluate the fulfilment of classification criteria for cryoglobulinemic vasculitis (CV) at diagnosis in a large cohort of patients with primary Sjögren syndrome (SS)…Abstract Number: 629 • 2015 ACR/ARHP Annual Meeting
Salivary Gland Ultrasonography As an Useful Tool to Distinguish Patients with Sjögren’s Syndrome at Risk for Non-Hodgkin’s Lymphoma Development
Background/Purpose: Salivary gland ultrasonography has been proposed as a promising novel tool for the diagnosis of primary Sjögren’s syndrome (SS). An increasing number of studies…Abstract Number: 630 • 2015 ACR/ARHP Annual Meeting
Can Extraglandular Manifestations Differentiate Primary Sjögren’s Syndrome from Sjögren’s-Systemic Lupus Erythematosus Overlap Syndrome?
Background/Purpose: Differentiating between primary Sjӧgren’s syndrome (PSS) with systemic manifestations (SM), and Sjӧgren’s -SLE overlap syndrome (OL) can be a clinical challenge. Approximately 30 %…Abstract Number: 631 • 2015 ACR/ARHP Annual Meeting
Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients
Background/Purpose: Sicca syndrome is a clinical presentation that is common for several systemic diseases that may infiltrate the exocrine glands. The most frequent disease is…Abstract Number: 632 • 2015 ACR/ARHP Annual Meeting
Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Background/Purpose: Circulating anti-Ro/SSA antibodies may rarely affect the adult conduction-system. A direct autoantibody-mediated electrophysiological inhibition of cardiomyocyte calcium-channels (acquired form) or an ante-natal subclinical injury…Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…Abstract Number: 634 • 2015 ACR/ARHP Annual Meeting
Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria
Background/Purpose: To analyse the epidemiological, clinical and immunological characteristics at diagnosis of the largest international cohort of patients diagnosed with primary Sjögren syndrome (SS) according…Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…Abstract Number: 636 • 2015 ACR/ARHP Annual Meeting
Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome
Background/Purpose: Anti-SSA/SSB antibodies represent the most specific serologic marker of Sjögren’s syndrome; however, in up to 30% of SS patients the test is negative.…Abstract Number: 637 • 2015 ACR/ARHP Annual Meeting
Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience
Background/Purpose: Recent insights from open studies and randomized clinical trials have shown the effectiveness of Rituximab (RTX) in controlling disease activity, patients’ subjective symptoms and…
ACR Meeting Abstracts